我要投票 腾药Tengyao在乌鸡白凤丸行业中的票数:223
· 外 推 电 报 ·
2025-02-05 18:00:24 星期三

【腾药Tengyao是哪个国家的品牌?】

腾药Tengyao是什么牌子?「腾药Tengyao」是 云南腾药制药股份有限公司 旗下著名品牌。该品牌发源于云南省保山市,由创始人赵丙贤在1990-06-22期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

云南腾药制药股份有限公司(以下简称“腾药”)成立于1956年,1997年改为股份合作制企业,2011年9月在县委政府的关心支持下完成股份制改造,同年11月与北京中证万融医药投资集团实现战略合作。

历经五十多年历史积淀的腾药,目前在编在岗员工600余人(含销售人员),具备了雄厚的制药技术基础,公司在不断汲取现代科学技术的基础上具备了专业的检测手段。两者的有机结合,使“腾药”产品有了过硬的质量,造就的品种有心脉隆注射液、安宫牛黄丸、人参再造丸、六味地黄丸、六灵丸、藿香正气水、感冒疏风片、清肺抑火片等。年生产规模为2000多吨,主要剂型有注射剂、丸剂(大蜜丸、小蜜丸、水丸、水蜜丸)、片剂、颗粒剂、散剂、酒剂、酊剂、糖浆剂,国药准字批文 130个,87个品种,137个品规,均是中药、天然药物。其中,国家二类新药“心脉隆注射液”由企业与大理学院联合研制,于2007年获准生产上市,为腾药的发展注入了新的活力。

规划:发展为以心脉隆注射液为主,传统普药为辅,日化保健品为补的上市企业。

党建:公司党总支下设5个党支部,共有党员62名(其中女党员37名)。

文化:公司起源于药王宫(建于明代天启六年)——全国中医药文化宣传教育基地,整个以求健康、传健康、学健康、食健康为主。公司秉承诚信制药,争做百年腾药。公司核心使命:“为人类健康创造卓越价值”,核心价值:“顾客第一服务他人 诚信 创新”。

诚信:公司一直秉承诚信制药的优良传承,用“宁为上药三分利,莫负良医九折肱”的对联警醒着一代又一代制药人。

创新:以心脉隆注射液为主的科研课题研究、美蠊系列日化保健品开发。


英文翻译:Yunnan tengyao Pharmaceutical Co., Ltd. (hereinafter referred to as "tengyao") was founded in 1956, changed into a joint-stock cooperative enterprise in 1997, completed the joint-stock transformation in September 2011 with the care and support of the county Party committee and government, and achieved strategic cooperation with Beijing Zhongzheng Wanrong pharmaceutical investment group in November of the same year. After more than 50 years of historical accumulation, tengyao has more than 600 employees (including sales staff) on the job at present, with a strong pharmaceutical technology foundation, and the company has a professional testing method based on continuous learning of modern science and technology. The organic combination of the two makes the "tengyao" products have excellent quality. The varieties created are Xinmailong injection, Angongniuhuang pill, Renshen Zaizai pill, Liuwei Dihuang pill, Liuling pill, Huoxiang Zhengqi water, Ganmao Shufeng tablet, Qingfei Yihuo tablet, etc. The annual production scale is more than 2000 tons, and the main dosage forms are injection, pill (big honey pill, small honey pill, water pill, water honey pill), tablet, granule, powder, liquor, tincture, syrup. There are 130 national drug approval documents, 87 varieties, 137 product specifications, all of which are traditional Chinese medicine and natural medicine. Among them, Xinmailong injection, a national second-class new drug, was jointly developed by the enterprise and Dali University, and was approved for production and listing in 2007, which injected new vitality into the development of tengyao. Planning: to develop into a listed enterprise mainly with Xinmailong injection, supplemented by traditional general medicine and supplemented by daily chemical health products. Party Construction: the company has 5 party branches under the general Party branch, with 62 party members (including 37 female party members). Culture: the company originated in the palace of Medicine (built in the sixth year of Tianqi in Ming Dynasty) - the national base of traditional Chinese medicine culture publicity and education, focusing on health, transmission, learning and eating. The company adheres to the integrity of pharmaceutical, striving to be a century drug. The company's core mission: "to create outstanding value for human health", and its core value: "customer first, serve others and innovate with integrity". Integrity: the company has always been adhering to the good heritage of integrity pharmaceutical, with the couplet of "better for the third profit of the drug, better for the nine fold arm" to alert generations of pharmaceutical people. Innovation: Research on Xinmailong injection as the main scientific research topic, and development of Periplaneta americana series of daily chemical health products.

本文链接: https://www.waitui.com/brand/19813d252.html 联系电话:08755133464

千城特选小程序码

7×24h 快讯

慈星股份:终止筹划购买武汉敏声控股权并配套募资事项,股票明起复牌

36氪获悉,慈星股份公告,公司因筹划发行股份及支付现金购买武汉敏声新技术有限公司控股权并募集配套资金事项,公司股票自2025年1月15日开市时起开始停牌。经交易相关方商讨研究决定终止筹划本次交易事项,公司股票将于2025年2月6日(星期四)开市起复牌。 截至公告日,交易各方未就本次交易具体方案、交易条件达成最终实质性协议。

刚刚

汇丰控股:昨日耗资约1.76亿港元回购219.76万股公司股份

36氪获悉,汇丰控股公告,公司于2月4日耗资约1.76亿港元回购219.76万股公司股份,每股回购价格79.6港元-80.45港元。

刚刚

印尼网约车巨头GoTo否认与Grab合并传闻

印尼网约车巨头GoTo当地时间2月4日提交文件,否认同竞争对手Grab的合并传闻。该公司称,“除实施股票回购外,未来12个月内没有任何重大行动计划”。此前有市场消息称,Grab与GoTo最近几周加快协商,认为今年是达成交易的有利时机。两家公司上市后均逐渐朝向取得盈利迈进,但竞争激烈导致价格无法调涨,同时挤压利润空间。据报道,过去几年双方一直在断断续续地协商,合并障碍包括双方之间的分歧,以及两家公司在印尼、新加坡等市场主导地位可能带来的反垄断问题。(界面)

刚刚

众鑫股份:泰国工厂一车间正式投产,预计2025年完成产量3万吨以上

36氪获悉,众鑫股份公告,公司泰国工厂一车间已顺利安装完毕,并于2025年1月8号开始调试设备并试机生产,2月1日顺利完成试机并正式投产。同时,二车间开始安装设备。公司预计2025年完成产量3万吨以上,2026年完成产量5万吨。此外,公司将根据国际市场的变化情况,决策是否对泰国工厂实施扩产计划。本次试机成功为公司拓展海外业务打下了基础,也验证了新装备的先进性,为今后的装备研发与升级提供了宝贵经验。

刚刚

杭州银行:2024年净利润169.83亿元,同比增长18.08%

36氪获悉, 杭州银行发布业绩快报,2024年度实现营业收入383.81亿元,同比增长9.61%;归属于上市公司股东的净利润169.83亿元,同比增长18.08%。截至2024年末,公司总资产21125.91亿元,较上年末增长14.73%;贷款总额9374.99亿元,较上年末增长16.16%;存款总额12725.51亿元,较上年末增长21.74%。

刚刚

本页详细列出关于中联的品牌信息,含品牌所属公司介绍,中联所处行业的品牌地位及优势。
咨询